FDA Panel votes 11-0 benefits outweigh risks of Onyx's (ONXX) carfilzomib
Tweet Send to a FriendGet Alerts ONXX Hot Sheet
Trade ONXX Now!
An FDA Panel has just voted 11-0 benefits outweigh risks of Onyx's (Nasdaq: ONXX) carfilzomib
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Brean Capital Raises Onyx (ONXX) Price Target to $115
- Peregrine Pharma (PPHM) Pops Higher on Resumption
- Echo Therapeutics (ECTE) Gets IRB Approval for Symphony CGM System
Create E-mail Alert Related Categories
FDA, Hot FDA News, Trading Halts
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
